GlassScriptPhysician profile
Nicholas Joseph Kamp
NPI 1417489923
$3,368.27
in general payments reported to CMS, 2019-2025
22 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,484 · 2024: $1,084 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.70 |
| Education | $237.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,167.12 | 2023-2025 | Navitor, Optis, Mitraclip |
| Medtronic, INC. | $581.53 | 2023-2025 | Corevalve Evolut R, Onyx Frontier |
| Edwards Lifesciences Corporation | $455.32 | 2023-2025 | Sapien 3 Ultra Resilia |
| Cardiovascular Systems INC. | $276.11 | 2023 | Diamondback Coronary |
| Boston Scientific Corporation | $186.75 | 2023-2025 | Opticross, General - Therapies, Avvigo Guidance System |
| Shockwave Medical, INC | $156.30 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $92.83 | 2025 | Ozempic, Wegovy |
| Biotronik INC. | $68.68 | 2023-2024 | Orsiro Mission, Recross, Pk Papyrus |
| Cardiva Medical, INC. | $64.23 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Bayer Healthcare Pharmaceuticals INC. | $61.44 | 2025 | |
| Stryker Corporation | $48.98 | 2025 | Artix Mt |
| Philips North America LLC | $32.00 | 2025 | Labosys |
| Novartis Pharmaceuticals Corporation | $30.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.30 | 2025 | Lifevest |
| Recor Medical INC | $21.95 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $18.87 | 2025 | Attruby |
| Pfizer INC. | $17.68 | 2025 | |
| Livanova USA, INC. | $17.60 | 2023 | Lifesparc |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2025 | Camzyos |
| Terumo Medical Corporation | $14.91 | 2024 | Metacross Otw |
| Chiesi USA, INC. | $13.65 | 2025 | Kengreal, Cleviprex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.